Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 4;2(1):18-26.
doi: 10.2991/chi.d.191121.001. eCollection 2020 Mar.

Clinical Advancement and Challenges of ex vivo Expansion of Human Cord Blood Cells

Oluwadunni E Emiloju  1 , Rashmika Potdar  2 , Vinicius Jorge  2 , Sorab Gupta  2 , Gabor Varadi  2
Affiliations
Review

Clinical Advancement and Challenges of ex vivo Expansion of Human Cord Blood Cells

Oluwadunni E Emiloju et al. Clin Hematol Int. .

Abstract

Apart from peripheral blood stem cell (PBSC), umbilical cord blood (UCB) is now a recognized source of stem cells for transplantation. UCB is an especially important source of stem cells for minority populations, which would otherwise be unable to find appropriately matched adult donors. UCB has fewer mature T lymphocytes compared with peripheral blood, thus making a UCB transplantation (UCBT) with a greater degree of HLA mismatch possible. The limited cell dose per UCB sample is however associated with delayed engraftment and a higher risk of graft failure, especially in adult recipients. This lower cell dose can be optimized by performing double unit UCBT, ex vivo UCB expansion prior to transplant and enhancement of the capabilities of the stem cells to home to the bone marrow. UCB contains naïve and immature T cells, thus posing significant challenges with increased risk of infections, graft versus host diseases (GVHD) and relapse following UCBT. Cell engineering techniques have been developed to circumnavigate the immaturity of the T cells, and include virus-specific cytotoxic T cells (VSTs), T cells transduced with disease-specific chimeric antigen receptor (CAR T cells) and regulatory T cell (Tregs) engineering. In this article, we review the advances in UCB ex vivo expansion and engineering to improve engraftment and reduce complications. As further research continues to find ways to overcome the current challenges, outcomes from UCBT will likely improve.

Keywords: Engraftment; Expansion; HSPC; Homing; Regulatory T cells; Transplantation; UCB; Umbilical cord blood.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflicts of interest.

References

    1. Baron F, Ruggeri A, Nagler A. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. Expert Rev Hematol. 2016;9:297–314. doi: 10.1586/17474086.2016.1128321. - DOI - PubMed
    1. Gluckman E, et al. Hematopoietic reconstitution in a patient with Fanconi's Anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174–8. doi: 10.1056/NEJM198910263211707. - DOI - PubMed
    1. Wagner JE, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood. 1992;79:1874–81. doi: 10.1182/blood.V79.7.1874.1874. - DOI - PubMed
    1. Laporte J-P, et al. Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. N Engl J Med. 1996;335:167–70. doi: 10.1056/NEJM199607183350304. - DOI - PubMed
    1. Stanevsky A, Goldstein G, Nagler A. Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev. 2009;23:199–204. doi: 10.1016/j.blre.2009.02.001. - DOI - PubMed